Trial Profile
A Phase I Study of OCV-501 in the Treatment of Patients with Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs OCV 501 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Otsuka Pharmaceutical
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 29 Sep 2011 New trial record